Hualan Biological's Associated Company Wins Regulatory Acceptance for Trastuzumab Injection Marketing Application
Stock News
Sep 23
Hualan Biological Engineering, Inc. (SZSE: 002007) has announced that its associated company, Hualan Ankang Biological Co., Ltd., received the Acceptance Notice from the National Medical Products Administration on September 22, 2026, for its marketing authorization application for trastuzumab for injection. The regulatory submission has been formally accepted for review.
Trastuzumab for injection is a monoclonal antibody targeting HER2, and its original branded product is Herceptin. It serves as a core first-line treatment for HER2-positive breast cancer and gastric cancer, with broad clinical applications and substantial market demand.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.